Cancer Epidemiology

项目摘要 癌症流行病学 莫菲特癌症中心（Moffitt）癌症流行病学（CE）项目的目标是减少癌症负担 通过更好地了解暴露、其生物标志物和潜在机制， 学习知识，为临床和公共卫生实践的进步提供信息。CE计划成员使用强大的 方法学和分析方法，包括广泛的生物标志物和综合方法， 进行人口水平的研究，告知癌症的病因，同时认识到许多方面的 在这组不同的疾病中的异质性。CE计划的创新研究延伸到整个 从癌症风险到拦截和早期发现到癌症结果的癌症连续体， 二级和三级预防，重点关注那些严重影响莫菲特的癌症 集水区行政长官成员努力将他们的研究成果转化为临床或公众的信息 卫生实践和政策，以及改变癌症预防和治疗模式。为了实现这些目标， 项目研究分为三个具体目标： 目的1：发现癌症风险的遗传易感性标志物，确定其功能，并利用这一点 精准预防信息。 目的2：识别和验证影响肿瘤发展的非遗传暴露及其生物标志物， 进展和结果，并使用这些知识来制定可行的癌症预防策略。 目的3：研究肿瘤和癌前病变的特征，这些特征影响早期发现、进展， 和结果，并利用这些发现为新的临床方法提供信息。 CE计划由来自八个学术部门的26名教师组成。同行评审资金为660万美元， 每年的直接成本，从NCI获得360万美元。这反映了16个R 01/R 01等值赠款。成员出版 905篇癌症相关学术文章（123篇高影响力;影响因子10）。行政长官举行十次同行评议 自2016年以来，已有2，371名参与者参与了干预试验。科学调查导致 帮助提高了对生物因素的认识-包括普通药物;人类 乳头状瘤病毒，艾滋病毒和其他病毒;遗传多态性;和放射基因组签名-对于多种 癌症是莫菲特集水区死亡率和发病率的主要贡献者。值得注意的是， CE成员的影响包括HPV疫苗接种政策的变化，卵巢癌解释的更新， 乳腺癌基因检测结果，以及黑色素瘤易感基因检测方案的指南变更 家庭行政长官成员目前还从事前列腺癌和肺癌的化学预防试验， 卵巢癌的临床试验，肺癌和胰腺癌的放射基因组学特征的开发， 前列腺癌的特异性基因表达谱影响临床和公共卫生。

PROJECT SUMMARY CANCER EPIDEMIOLOGY PROGRAM The goal of the Moffitt Cancer Center (Moffitt) Cancer Epidemiology (CE) Program is to reduce cancer burden through better knowledge of exposures, their biological markers, and underlying mechanisms, and to translate learned knowledge to inform advances in clinical and public health practice. CE Program Members use robust methodologic and analytic approaches that incorporate a broad array of biomarkers and integrative methods to conduct population-level research that informs the etiology of cancer while recognizing the many aspects of heterogeneity in this diverse group of diseases. The innovative research of the CE Program extends across the cancer continuum from cancer risk to interception and early detection to cancer outcomes covering primary, secondary, and tertiary prevention, with an intentional focus on those cancers that heavily impact Moffitt’s catchment area. CE Members strive to translate their research findings to inform change in clinical or public health practice and policy, and to shift cancer prevention and treatment paradigms. To achieve these goals, CE Program research is organized into three Specific Aims: Aim 1: To discover inherited susceptibility markers of cancer risk, determine their function, and leverage this information for precision prevention. Aim 2: To identify and validate non-genetic exposures and their biomarkers affecting tumor development, progression, and outcome, and use this knowledge to develop actionable cancer prevention strategies. Aim 3: To investigate features of tumors and premalignant conditions that influence early detection, progression, and outcomes and capitalize on these findings to inform novel clinical approaches. The CE Program consists of 26 faculty from eight academic departments. Peer-reviewed funding is $6.6M in annual direct costs, with $3.6M from the NCI. This reflects 16 R01/R01-equivalent grants. Members published 905 cancer-relevant scholarly articles (123 high impact; impact factor ³ 10). CE Members hold 10 peer-reviewed MPI awards and have accrued 2,371 participants onto intervention trials since 2016. Scientific investigations led by Members have helped advance knowledge of biological factors – including common medicines; human papilloma virus, HIV, and other viruses; genetic polymorphisms; and radiogenomic signatures – for multiple cancers that are major contributors to mortality and morbidity in Moffitt’s catchment area. Notably, translational impact of CE Members includes changes in HPV-vaccination policy, updates for the interpretation of ovarian and breast cancer genetic testing results, and guideline changes for genetic testing protocols for melanoma-prone families. CE Members also are currently engaged in chemoprevention trials in prostate and lung cancer, aspirin trials in ovarian cancer, developing radiogenomic signatures in lung and pancreatic cancer, and identifying race- specific gene expression profiles in prostate cancer to impact clinical and public health.